Company JW Pharmaceutical Corporation

A001060

KR7001060003

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for JW Pharmaceutical Corporation

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
29,800 ^KRW	-2.30%		0.00%	-16.17%

Mar. 14	JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 22	CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	MT

JW Pharmaceutical Corp is a Korea-based company engaged in the development and manufacture of pharmaceutical products. The Company mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The Company also researches and develops anticancer drugs.

Number of employees: 1,197

KRW in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	684,351	100.0 %	748,527	100.0 %	+9.38%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	684,351	100.0 %	748,527	100.0 %	+9.38%

Managers	Title	Age	Since
Seong-Yeol Lee CEO	Chief Executive Officer	61	-
Yeong-Seob Shin CEO	Chief Executive Officer	61	-
Kyung-Ha Lee CHM	Chairman	60	-

Members of the board	Title	Age	Since
Kyung-Ha Lee CHM	Chairman	60	-
Seong-Yeol Lee CEO	Chief Executive Officer	61	-
Gyu-Eon Jung BRD	Director/Board Member	62	-
Yeong-Seob Shin CEO	Chief Executive Officer	61	-
Yong-Gwan Kim BRD	Director/Board Member	56	-
Bi-Ho Jeon BRD	Director/Board Member	67	19-03-28
Jung-Hwan Han BRD	Director/Board Member	64	19-03-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	341,871	187,476 ( 54.84 %)	4,013 ( 1.174 %)	52.98 %
Stock B	0	1,063,535	0	0
Stock C	1	23,280,123	13,000,887 ( 55.85 %)	290,334 ( 1.247 %)
Stock D	0	209,912	0	3,040 ( 1.448 %)

Name	Equities	%	Valuation
JW HOLDINGS CORPORATION 46.68 %	10,870,683	46.68 %	263 M ₩
JW PHARMACEUTICAL CORPORATION 1.272 %	296,141	1.272 %	7 M ₩
Kyung-Ha Lee 0.6105 %	142,160	0.6105 %	3 M ₩
Dimensional Fund Advisors Ltd. 0.0190 %	4,429	0.0190 %	107 250 ₩
JW Pharmaceutical Corp. Employee Stock Ownership Association 0.0178 %	4,145	0.0178 %	100 373 ₩
DFA Australia Ltd. 0.0172 %	4,012	0.0172 %	97 152 ₩
Mirae Asset Global Investments Co., Ltd. 0.004166 %	970	0.004166 %	23 489 ₩
Ja-eok Ku 0.002517 %	586	0.002517 %	14 190 ₩
Jin-sook Kim 0.002478 %	577	0.002478 %	13 972 ₩
Korea Investment Management Co., Ltd. 0.000322 %	75	0.000322 %	1 816 ₩

Name	Equities	%	Valuation
JW HOLDINGS CORPORATION 3.593 %	7,544	3.593 %	332 300 ₩

Name	Equities	%	Valuation
JW HOLDINGS CORPORATION 99.31 %	1,063,535	99.31 %	26 M ₩

Name	Equities	%	Valuation
JW PHARMACEUTICAL CORPORATION 1.197 %	4,093	1.197 %	93 033 ₩

Name	Equities	%	Valuation
JW PHARMACEUTICAL CORPORATION 1.20%	4,093	1.20%	93,033 $

JW PHARMACEUTICAL Corp.

JW Tower 2477 Nambusunhwan-ro

06725, Seoul

http://www.jw-pharma.co.kr

address JW Pharmaceutical Corporation(A001060)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29,800 KRW

Average target price

41,667 KRW

Spread / Average Target

+39.82%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
JW PHARMACEUTICAL CORPORATION	-16.17%	517M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals